PMID- 34466455
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2322-2379 (Electronic)
IS  - 2588-2767 (Print)
IS  - 2322-2379 (Linking)
VI  - 8
DP  - 2019
TI  - Neuroprotective Effect of Pentoxifylline on 
      3,4-Methylenedioxymethamphetamine-Induced Apoptosis in CA1 Cells of Wistar Rat 
      Hippocampus.
PG  - e963
LID - 10.31661/gmj.v8i0.963 [doi]
AB  - BACKGROUND: 3,4-Methylenedioxymethamphetamine is psychoactive and hallucinogenic 
      and has been shown to produce neurotoxicity both in animals and in humans. 
      Recently, vasodilator drugs such as pentoxifylline (PTX) have been introduced as 
      an alternative with neuroprotective effects. There is no study about the 
      protective effect of PTX on hippocampal apoptosis due to high-dose administration 
      of 3,4-Methylenedioxymethamphetamine (MDMA), so in this study, the protective 
      effect of PTX on the hippocampus of male Wistar rats following high-dose of the 
      drug has been investigated. MATERIALS AND METHODS: Twenty-four male Wistar rats 
      weighing 250-300 g were randomly divided into four groups: control, sham (MDMA 
      injection), experimental (MDMA+PTX injection), and vehicle (MDMA+saline) groups. 
      Two weeks later, the brains were removed and prepared for TUNEL and western blot 
      techniques. Concomitantly the hippocampus was removed to study the change in 
      Bcl-2 and BAX mRNA expression with quantitative real-time polymerase chain 
      reaction. RESULTS: Data showed that the number of apoptotic bodies significantly 
      decreased in the experimental group compared to the other groups, except for in 
      control. Also, further investigation revealed that BAX reduced considerably, 
      while Bcl-2 mRNA expression increased dramatically after PTX treatment. 
      CONCLUSIONS: Our results suggest that PTX may be a neuroprotective agent, and its 
      neuroprotective potential may contribute to reducing the severity of lesions in 
      the hippocampus following a high dose administration of MDMA.
CI  - Copyright(c) 2019, Galen Medical Journal.
FAU - Movassaghi, Shabnam
AU  - Movassaghi S
AD  - Department of Anatomical Sciences and Cognitive Neuroscience, Faculty of 
      Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
FAU - Khazaei Koohpar, Zeinab
AU  - Khazaei Koohpar Z
AD  - Department of Cellular and Molecular Biology, Faculty of Biological Sciences, 
      Tonekabon Branch, Islamic Azad University, Tonekabon, Iran.
FAU - Hashemi, Mehrdad
AU  - Hashemi M
AD  - Department of Genetics, Faculty of Advanced Sciences and Technology, Islamic Azad 
      University, Tehran Medical Sciences, Tehran, Iran.
FAU - Jafari Semnani, Sourena
AU  - Jafari Semnani S
AD  - Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Sharifi, Zahra Nadia
AU  - Sharifi ZN
AD  - Department of Anatomical Sciences and Cognitive Neuroscience, Faculty of 
      Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20190807
PL  - Iran
TA  - Galen Med J
JT  - Galen medical journal
JID - 101625418
PMC - PMC8344151
OTO - NOTNLM
OT  - 3,4-Methylenedioxymethamphetamine
OT  - Apoptosis
OT  - Hippocampus
OT  - Pentoxifylline
EDAT- 2019/08/07 00:00
MHDA- 2019/08/07 00:01
PMCR- 2019/08/07
CRDT- 2021/09/01 07:26
PHST- 2017/07/28 00:00 [received]
PHST- 2017/11/17 00:00 [revised]
PHST- 2018/05/05 00:00 [accepted]
PHST- 2021/09/01 07:26 [entrez]
PHST- 2019/08/07 00:00 [pubmed]
PHST- 2019/08/07 00:01 [medline]
PHST- 2019/08/07 00:00 [pmc-release]
AID - 10.31661/gmj.v8i0.963 [doi]
PST - epublish
SO  - Galen Med J. 2019 Aug 7;8:e963. doi: 10.31661/gmj.v8i0.963. eCollection 2019.